Butorphanol Tartrate Preservative Free en es it fr

Butorphanol Tartrate Preservative Free Brand names, Butorphanol Tartrate Preservative Free Analogs

Butorphanol Tartrate Preservative Free Brand Names Mixture

  • No information avaliable

Butorphanol Tartrate Preservative Free Chemical_Formula

C21H29NO2

Butorphanol Tartrate Preservative Free RX_link

http://www.rxlist.com/cgi/generic2/butor.htm

Butorphanol Tartrate Preservative Free fda sheet

Butorphanol_Tartrate_Preservative_Free FDA

Butorphanol Tartrate Preservative Free msds (material safety sheet)

Butorphanol_Tartrate_Preservative_Free MSDS

Butorphanol Tartrate Preservative Free Synthesis Reference

No information avaliable

Butorphanol Tartrate Preservative Free Molecular Weight

327.461 g/mol

Butorphanol Tartrate Preservative Free Melting Point

No information avaliable

Butorphanol Tartrate Preservative Free H2O Solubility

Moderate

Butorphanol Tartrate Preservative Free State

Solid

Butorphanol Tartrate Preservative Free LogP

4.176

Butorphanol Tartrate Preservative Free Dosage Forms

Drops; Drug premix; Gel; Globules; Liquid; Powder for solution; Solution; Spray; Tablet

Butorphanol Tartrate Preservative Free Indication

For the management of pain when the use of an opioid analgesic is appropriate. Also indicated as a preoperative or preanesthetic medication, as a supplement to balanced anesthesia, and for the relief of pain during labor.

Butorphanol Tartrate Preservative Free Pharmacology

Butorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord.

Butorphanol Tartrate Preservative Free Absorption

Rapidly absorbed after intramuscular injection and peak plasma levels are reached in 20-40 minutes. The absolute bioavailability is 60-70% and is unchanged in patients with allergic rhinitis. In patients using a nasal vasoconstrictor (oxymetazoline) the fraction of the dose absorbed was unchanged, but the rate of absorption was slowed. Oral bioavailability is only 5-17% because of extensive first-pass metabolism.

Butorphanol Tartrate Preservative Free side effects and Toxicity

The clinical manifestations of butorphanol overdose are those of opioid drugs in general. The most serious symptoms are hypoventilation, cardiovascular insufficiency, coma, and death.

Butorphanol Tartrate Preservative Free Patient Information

Butorphanol Tartrate Preservative Free Organisms Affected

Humans and other mammals